KOSDAQRetail & Consumer335870

Wing's Foot

₩3,740▼ 4.96%2026-11-18 close
Market Cap
₩12.5B
Turnover
₩700M
Volume
180K
Shares out.
3.4M
PER
—
PBR
0.5×
EPS
-₩1,995
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Wing's Foot: Medical AI Pivot Under Continued Losses

Wing's Foot's sales have fallen for three straight years since 2023, it swung to an operating loss in 2025, and it has posted operating losses for five consecutive quarters while shifting its business toward medical AI.

  1. 1

    The company swung to an operating loss of KRW 2.8 billion in 2025, and its operating margin fell from 7.7% in 2023 to -6.7% in 2025.

  2. 2

    After it stopped distributing Bearpaw products in January 2026, first-quarter 2026 revenue fell 92.2% from the prior quarter to KRW 1.45 billion.

  3. 3

    Revenue rose for two straight quarters to KRW 2.95 billion in the third quarter of 2026, yet the operating loss widened to KRW 2.06 billion.

  4. 4

    Year-end 2025 total equity was KRW 31.5 billion against total liabilities of KRW 22.9 billion, a debt ratio of 72.8%.

  5. 5

    The company signed a medical solution supply contract with W.AI and is expanding into medical AI and wellness.

02

Business structure

Wing's Foot distributes footwear, apparel and leather goods, and it listed on KOSDAQ in December 2019. Based on second-quarter 2026 revenue, its mix was global brands 62%, its own WINGS FOOT brand 18%, private label and others 16%, and FESSURA 4%.

Bearpaw had been a cash cow among its key brands, and the company stopped distributing Bearpaw products in January 2026. It sold Bearpaw inventory in a lump sum for about KRW 7 billion to secure firm cash flow and to reduce inventory management and other operating costs.

The company said that losing a key brand makes a short-term shrinkage in sales unavoidable. In its semi-annual report it set out a plan to move beyond a distribution-centered structure into higher-value, technology-based businesses.

The first step is a medical solution supply contract with W.AI, and the company plans to widen its network of medical institutions and upgrade its AI performance with clinical data.

The business is seasonal: revenue rose from KRW 7.52 billion in the third quarter of 2025 to KRW 18.6 billion in the fourth quarter, reflecting concentrated winter product sales.

In scale, annual revenue of KRW 42 billion is small next to large retailers such as Shinsegae, E-Mart and Lotte Shopping, which share its sector classification.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩7.5B-₩500M−7.0%
2025Q4₩18.6B-₩400M−2.1%
2026Q1₩1.5B-₩4.4B−304.6%
2026Q2₩1.8B-₩1.9B−110.6%
2026Q3₩3B-₩2.1B−69.7%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩54.3B₩3.7B-₩16.8B6.8%−65.8%84.9%
2023₩51.6B₩4B₩3.3B7.7%11.1%45.2%
2024₩46.5B₩1.9B₩1.2B4.1%3.8%55.3%
2025₩42B-₩2.8B-₩1.8B−6.7%−5.6%72.8%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-14

04

Earnings analysis

Annual revenue fell from KRW 54.3 billion in 2022 to KRW 51.6 billion in 2023 (down 5.1% year on year), KRW 46.5 billion in 2024 (down 9.9%) and KRW 42 billion in 2025 (down 9.8%), a decline for three straight years from 2023 to 2025. Among 2022 to 2025, 2022 was the largest year and 2025 the smallest.

Operating profit rose from KRW 3.71 billion in 2022 to KRW 3.98 billion in 2023 (up 7.3%), then fell to KRW 1.89 billion in 2024 (down 52.5%) and turned into an operating loss of KRW 2.8 billion in 2025.

The operating margin moved from 6.8% in 2022 and 7.7% in 2023 to 4.1% in 2024 and -6.7% in 2025, so margin pressure coincided with falling sales. In its 2025 results announcement dated February 11, 2026, the company attributed the decline to weak winter core products caused by external factors such as abnormal weather.

Net income attributable to controlling shareholders went from a loss of KRW 16.8 billion in 2022 to KRW 3.33 billion in 2023, a turn to profit, then KRW 1.2 billion in 2024 (down 64.0%) and a loss of KRW 1.77 billion in 2025.

Net income including non-controlling interests shows the same amounts in each year from 2022 to 2025. The debt ratio went from 84.9% in 2022 to 45.2% in 2023, then 55.3% in 2024 and 72.8% in 2025.

Year-end 2025 total equity of KRW 31.5 billion was all attributable to controlling shareholders, against total liabilities of KRW 22.9 billion. Operating cash flow went from KRW 1.54 billion in 2022, KRW 4 billion in 2023 and KRW 1.84 billion in 2024 to -KRW 4.21 billion in 2025.

Quarterly, fourth-quarter 2025 revenue of KRW 18.6 billion rose 147.7% from the prior quarter, but the operating loss was KRW 387 million.

First-quarter 2026 revenue fell 92.2% to KRW 1.45 billion, coinciding with the timing of the Bearpaw break, and the operating loss of KRW 4.43 billion and net loss attributable to controlling shareholders of KRW 7.16 billion were the largest of the last five quarters.

Revenue then rose to KRW 1.76 billion in the second quarter and KRW 2.95 billion in the third quarter of 2026, two consecutive quarterly increases, while operating losses stayed at KRW 1.94 billion and KRW 2.06 billion.

The net loss attributable to controlling shareholders over the last four quarters, from the fourth quarter of 2025 to the third quarter of 2026, totals KRW 6.68 billion.

05

Industry analysis

Footwear and apparel distribution is heavily seasonal and sensitive to weather, and the abnormal temperatures the company cited for weak 2025 winter sales show this exposure. When winter products do not sell, inventory burden grows at the same time.

Distribution demand is strongly influenced by consumer sentiment and shifts in sales channels. Large listed retailers lead in store networks and purchasing scale, while Wing's Foot's annual revenue of about KRW 42 billion leaves a wide gap in size.

In portfolio terms, global brands are the largest share at 62% and its own WINGS FOOT brand accounts for 18%. How this structure is rebuilt after the loss of a key brand will shape its position within the industry.

The medical AI field does not directly overlap with its existing footwear distribution capabilities, so clinical data and technical capability are the core conditions for entry. The company cited rapid growth in the AI and digital healthcare industry as the basis for its restructuring.

It is approaching this field by continuing to expand collaboration models built on AI technology and clinical experience.

06

Outlook

The central axis of the 2026 business is expansion into medical AI and wellness. Building on its supply contract with W.AI, the company plans to widen its network of medical institutions and upgrade its AI performance using clinical field data.

It has also set out a plan to apply its existing distribution capabilities to the new areas and improve profitability over the medium to long term. The company said the one-time sale of Bearpaw inventory for about KRW 7 billion brings firm cash flow and lower operating costs.

However, it acknowledged that a short-term shrinkage in sales is unavoidable, and third-quarter 2026 revenue fell 60.8% year on year, so sales remain well below the prior-year level.

On the shareholder side, Chief Executive Im Sin-young, described as the de facto controlling shareholder, increased his common shares by 29,179 between September 2 and October 26, 2026 through on-market purchases, and his holding reached 340,985 shares, or 10.18%, as of November 4, 2026.

The 10%-plus shareholder Motiva Korea sold 479,616 convertible bonds off-market on October 30, 2026, and the company disclosed that the sale followed its early acquisition of the bonds before maturity. As a result, the share of convertible bonds held fell from 39.80% to 33.34% as of November 6, 2026.

The next regular report is the 2026 annual report, which is expected to show how much the business restructuring is reflected in revenue.

07

Valuation

PER
—
PBR
0.5×
ROE
-25.9%
EPS
-₩1,995
BPS
₩7,000
Dividend per share
₩0

Because the company has posted net losses over the last four quarters, a price-to-earnings ratio cannot be calculated on an earnings basis. Its price-to-book ratio is below 1 times, meaning the share price sits under book value per share.

Total equity of KRW 31.5 billion is entirely attributable to controlling shareholders, which gives a clear base for comparing net assets. The dividend yield is below the industry average, so shareholder returns through dividends play a limited role.

Over several years, the picture moved from a turn to profit in 2023 to a turn to loss in 2025, and the operating margin fell from 7.7% in 2023 to -6.7% in 2025.

Without a recovery in earnings, earnings-based multiples offer a weak basis for comparison, so net assets and operating metrics become the main reference points. Comparing the price-to-book ratio with its past band shows where the share price stands relative to net assets.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-14

08

Bull factors

Attempt to expand into medical AI

The company said it signed a medical solution supply contract with W.AI and announced a plan to widen its network of medical institutions. It intends to apply its distribution capabilities to medical AI and wellness to create new revenue sources.

If the restructuring turns into actual revenue, it could mark a turning point away from the loss-making structure, which is the bullish case.

Consecutive quarterly revenue recovery

Second-quarter 2026 revenue rose 20.7% from the prior quarter to KRW 1.76 billion, and third-quarter revenue rose 68.1% to KRW 2.95 billion, two straight quarterly increases. Fourth-quarter 2025 revenue of KRW 18.6 billion shows how much the top line can grow when winter product demand concentrates.

The fourth quarter of 2026 overlaps with the winter season, so whether the recovery holds becomes a point to verify.

Financial capacity and cash generation

The debt ratio at year-end 2025 was 72.8%, below 84.9% in 2022, and total equity stood at KRW 31.5 billion. The company said the lump-sum sale of Bearpaw inventory for about KRW 7 billion secured firm cash.

Its turn to a net profit attributable to controlling shareholders in 2023 is also cited as evidence of earning capacity.

09

Bear factors

Five consecutive quarters of operating losses

The company has posted operating losses for five consecutive quarters from the third quarter of 2025 through the third quarter of 2026. The third-quarter 2026 operating loss of KRW 2.06 billion widened from KRW 1.94 billion in the prior quarter.

The net loss attributable to controlling shareholders over the last four quarters totals KRW 6.68 billion, and the first quarter of 2026 alone recorded KRW 7.16 billion.

Sales contraction after losing a key brand

First-quarter 2026 revenue fell 92.2% from the prior quarter to KRW 1.45 billion. Third-quarter 2026 revenue fell 60.8% year on year and remains well below the prior-year level.

The company itself acknowledged that the loss of a key brand makes a short-term shrinkage in sales unavoidable, so the revenue base stays thin until the restructuring takes hold.

Cash flow and profitability decline

The operating margin fell from 7.7% in 2023 to -6.7% in 2025. Operating cash flow turned to -KRW 4.21 billion in 2025. The company attributed the 2025 weakness to poor winter core product sales caused by abnormal weather, and if weather disruptions recur, a similar pattern could repeat.

10

Risk factors

Seasonality and weather

Because winter core products drive results, repeated abnormal weather would widen swings in revenue. The gap between fourth-quarter 2025 revenue of KRW 18.6 billion and third-quarter revenue of KRW 7.52 billion illustrates this structure. Given the nature of seasonal goods, a weather miss also adds to inventory management burden.

Execution of the restructuring

The shift into medical AI depends on new technical capability, clinical data and collaboration models with medical institutions. The company said it will keep expanding its collaboration model, but the contract scale and the timing of any revenue contribution are not yet reflected in reported results.

If new businesses fail to fill the revenue gap left by the lost brand, the loss-making structure could become prolonged.

Ownership and financial capacity

The chief executive reportedly increased his holdings through on-market purchases in September and October 2026. The 10%-plus shareholder's share of convertible bonds fell to 33.34% after an off-market sale on October 30, 2026, which the company disclosed as following its early bond acquisition. The debt ratio rose to 72.8% in 2025 from 55.3% in 2024, so financial room is narrower than before.

11

What to watch next

  1. After December 2026 (ad hoc disclosures)

    Whether the W.AI and other medical solution contracts begin contributing revenue and at what scale. This is the first point at which the restructuring would show up in sales.

  2. Around February 2027

    Preliminary annual results for fiscal 2026. The 2025 preliminary results were disclosed on February 11, 2026. This is where the fourth-quarter 2026 sales and operating result can be checked against the loss trend.

  3. By March 31, 2027

    Filing of the 2026 annual report. Full-year revenue, operating margin and debt ratio will be fixed, and the annual impact of the Bearpaw break will become visible.

  4. By May 15, 2027

    The first-quarter 2027 quarterly report. Comparing against first-quarter 2026 revenue of KRW 1.45 billion will show whether sales are recovering and whether the operating loss has narrowed.

12

Overall view

Wing's Foot swung to an operating loss of KRW 2.8 billion in 2025 after turning to profit in 2023, as falling sales and a lower operating margin occurred together.

Its exit from Bearpaw distribution in January 2026 sharply reduced sales, and first-quarter 2026 revenue was KRW 1.45 billion with an operating loss of KRW 4.43 billion. Revenue then rose for two straight quarters, but operating losses of KRW 1.94 billion and KRW 2.06 billion persisted.

On the balance sheet, the 2025 debt ratio of 72.8% is below 84.9% in 2022, and total equity of KRW 31.5 billion exceeds total liabilities of KRW 22.9 billion.

On the other side, operating cash flow turned to -KRW 4.21 billion in 2025, and the net loss attributable to controlling shareholders over the last four quarters totals KRW 6.68 billion.

The bullish factors are the medical AI supply contract, the restructuring intent and the possibility of winter product demand recovering, while the bearish factors are continued losses and the sales contraction after losing a key brand.

Whether the restructuring translates into revenue and operating profit is the first point to verify in the 2026 annual report.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 17 more articles and sources
  1. comp.fnguide.com
  2. butler.works
  3. digitaltoday.co.kr
  4. ibtomato.com
  5. news.nate.com
  6. markets.hankyung.com
  7. edaily.co.kr
  8. m.news.nate.com
  9. tradingkey.com
  10. kr.investing.com
  11. sec.gov
  12. stockstory.org
  13. digitaltoday.co.kr
  14. judal.co.kr
  15. stocktwits.com
  16. digitaltoday.co.kr
  17. judal.co.kr

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis